Clinical Context The GLP-1 receptor agonist (GLP-1 RA) class has expanded dramatically, with agents differentiated by dosing frequency (daily vs.…
Browsing: PICO
Clinical Context GLP-1 receptor agonists produce substantial weight loss, but the mechanisms underlying this effect have been debated. Is weight…
Clinical Context Heart failure with preserved ejection fraction (HFpEF) represents one of the most challenging conditions in cardiovascular medicine. Unlike…
Clinical Context Type 2 diabetes ultimately results from beta-cell failure—the inability of pancreatic beta cells to produce sufficient insulin to…
Summary: In 1,145 patients with obesity-related HFpEF (LVEF ≥45%, BMI ≥30 kg/m²) from the pooled STEP-HFpEF trials, semaglutide 2.4 mg…
Clinical Context Polycystic ovary syndrome (PCOS) affects 6-12% of reproductive-age women and extends far beyond reproductive concerns. It’s increasingly recognized…
Summary: In adults with chronic hypoparathyroidism requiring conventional therapy with calcium and active vitamin D, TransCon PTH (palopegteriparatide) once daily…
Clinical Context The concept of type 2 diabetes “remission”—achieving normal glycemia without diabetes medications—has been revolutionized by intensive dietary intervention…
Summary: In adults with chronic kidney disease (eGFR ≥25, UACR 30-3,500 mg/g) and overweight/obesity (BMI ≥27) without diabetes, semaglutide 2.4…
Clinical Context Diabetic foot ulcers (DFUs) are traditionally managed with wound care, offloading, infection control, and vascular optimization. Exercise is…